et al. Randomised, multicentre phase III study of saquinavir plus zidovudine plus zalcitabine in previously untreated or minimally pretreated HIV-infected patients. Clin Drug Invest 2000; 20: 295–307.
et al. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther 1998; 3: 33–42.
et al. Disposition and bioavailability of the HIV-proteinase inhibitor Ro-31–8959 after single doses in healthy volunteers. Br J Clin Pharmacol 1992; 34: 155P–156P. , ,
Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 195–196.
et al. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. AIDS 1998; 12: F103–F109.
et al. TIDBID study 48 week analysis: fortovase™ (FTV) TID regimen compared with FTV BID or FTV + NFV BID regimens in HIV-1 infected patients. 13th International AIDS Conference. Durban, South Africa, 914 July 2000 Abstract TupeB2229., ,
Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokinet 1999; 37: 75–86.
, , , .
et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996; 124: 1039–1050.
Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44: 190–194.
, , .
Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small intestinal cytochrome P4503A4. Potential contribution to high first-pass metabolism. Drug Metab Disposit 1997; 25: 256–266.
et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997; 11: F29–F33.
et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63: 453–464.
Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275–291.
, , .
Saquinavir is a high affinity substrate for the multidrug transporter, P-glycoprotein. Clin Pharmacol Ther 1997; 61: 193. , , , .
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129–134.
, , .
et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus mini-dose ritonavir in HIV-negative adults. Antimicrob Agents Chemother 2000; 44: 2672–2678.
et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999; 13: 213–234.DOI: 10.1097/00002030-199902040-00009
Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. AIDS 1998; 12: 1400–1402.
et al. Efficacy of a five-drug combination of ritonavir, saquinavir and efavirenz in patients who failed on conventional triple drug regime: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999; 13: F71–F77.
Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with ‘baby-dose’ ritonavir. Eur J Med Res 1999; 4: 101–104.
, , , , .
Pharmacokinetic (PK) drug interaction with saquinavir soft gelatin capsule. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 2629 September 1999 [Poster 339. , .
et al. Saquinavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 2001; 52: 255–264.
The effect of ritonavir on increases in saquinavir plasma concentration is independent of ritonavir dosage. Combined analysis of 120 subjects. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17–22 September 2000 [Abstract 1650. , , .
Pharmacokinetics, 2nd edn. New York, Marcel Dekker, 1982. , .
Effects of ritonavir on saquinavir plasma concentration. analysis of 271 patients in routine clinical practice. AIDS 2000; 14 (Suppl. 4): S91 [ Poster P261A. , , , , .
Discontinuation rates for protease inhibitor regimens containing ritonavir 600mg versus ritonavir 400mg plus saquinavir 400mg. Ann Pharmacother 1999; 33: 899–905.
, , , .
et al. High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive inhibitor-experienced patients and predictors of virologic response. J Acquir Immune Defic Syndr 1999; 22: 132–138.
et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42: 3218–3224.
et al. The steady state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999; 13: F95–F99.DOI: 10.1097/00002030-199910010-00001
Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) and ritonavir (RTV) combinations in a once-daily regimen in healthy volunteers (Merck 089). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2629 September 1999 [Abstract 329. , , , .
Pharmacokinetic (PK) drug interaction between amprenavir (APV) and ritonavir (RTV) in HIV-seronegative subjects after multiple oral dosing. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 30 January2 February 2000 [Abstract 77. , , , , , .
et al. Combination therapy with saquinavir soft gelatin capsules plus nucleoside antiretroviral agents in HIV-infected children. 12th World AIDS Conference. Geneva, Switzerland, 28 June3 July 1998 [Poster 12260. , ,
Therapeutic drug monitoring in the management of subjects on the protease inhibitors nelfinavir and saquinavir: results of the Roche UK TDM Service. AIDS 2000; 14 (suppl. 4): S89 [ Poster P259. , , , , , .
et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21–30.
et al. Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz. AIDS 2000; 14: 626–628.
Saquinavir soft-gel capsule. An updated review of its use in the management of HIV infection. Drugs 2000; 60: 481–516.
et al. Pharmacokinetics of the triple combination of saquinavir, ritonavir, and efavirenz in HIV-positive patients. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA 30 January 2 February 2000 [Abstract 79. , ,
Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999; 29: 1586.
, , , , .